359 results on '"Bolwell, Brian J."'
Search Results
2. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
3. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors
4. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study.
5. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
6. Leadership: What Are We Looking for?
7. Givers & Takers
8. Moments
9. Straight Talk: Todayʼs Cancer Centers: Meetings
10. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
11. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
12. Good Judgment
13. COVID-19 & Leadership
14. The Paradox of Empathy
15. On the Other Hand
16. Values
17. Conflict & New Tools
18. Physician Evaluation
19. Supplemental Table 1 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
20. Supplemental Figure 1 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
21. Supplemental Table 2 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
22. Supplemental Table 3 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
23. Supplemental Table 4 from Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
24. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times–Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation
25. When Were You at Your Best?
26. Leadership & Relationships
27. Annual Meetings
28. What We Do
29. On Criticism
30. Foresight
31. Let It Go
32. Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort
33. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation
34. Chip-Derived Vs De Novo Treatment-Related Myeloid Neoplasms after Autologous Stem Cell Transplant for Lymphoid Disorders
35. Outcasts
36. Questions
37. Change
38. Learning the Leadership Levels in Your Cancer Center
39. I Donʼt Know
40. Ghosts 2: Understanding Fear & Death
41. The Art of Preaching
42. Talk to People
43. Prospective Clinical Study of Precision Oncology in Solid Tumors
44. How to Deliver Results
45. What Leadership Books Do Not Tell You
46. The Power of Kindness
47. Joe Simone & Leadership
48. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma
49. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma
50. Trust Revisited
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.